Edwards Lifesciences Corporation $EW Holdings Trimmed by Liontrust Investment Partners LLP

Key Points

• Liontrust Investment Partners LLP reduced its stake in Edwards Lifesciences by 5.7%, owning 1.5 million shares valued at approximately $110 million.
• Insider Larry L. Wood sold 8,950 shares at an average price of $75.23, decreasing his ownership by 4.15%.
• Edwards Lifesciences reported a quarterly revenue of $1.53 billion, exceeding analysts' estimates and reflecting an 11.9% increase year-over-year.

Liontrust Investment Partners LLP decreased its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 5.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,518,152 shares of the medical research company's stock after selling 92,287 shares during the quarter. Edwards Lifesciences accounts for approximately 1.7% of Liontrust Investment Partners LLP's holdings, making the stock its 23rd largest position. Liontrust Investment Partners LLP owned 0.26% of Edwards Lifesciences worth $110,036,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Brighton Jones LLC acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $266,000. Bank Pictet & Cie Europe AG boosted its holdings in shares of Edwards Lifesciences by 16.7% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company's stock valued at $757,000 after buying an additional 1,463 shares during the period. Townsquare Capital LLC grew its position in shares of Edwards Lifesciences by 24.8% during the 4th quarter. Townsquare Capital LLC now owns 6,501 shares of the medical research company's stock valued at $481,000 after buying an additional 1,293 shares during the last quarter. CreativeOne Wealth LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth about $201,000. Finally, United Capital Financial Advisors LLC lifted its holdings in Edwards Lifesciences by 64.8% in the fourth quarter. United Capital Financial Advisors LLC now owns 24,859 shares of the medical research company's stock worth $1,840,000 after acquiring an additional 9,779 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

NYSE:EW traded up $2.3440 during mid-day trading on Wednesday, reaching $81.2740. 5,058,602 shares of the stock were exchanged, compared to its average volume of 4,834,787. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The business has a fifty day moving average price of $77.35 and a 200 day moving average price of $74.54. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00. The firm has a market capitalization of $47.72 billion, a PE ratio of 11.69, a PEG ratio of 3.81 and a beta of 1.08.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the company earned $0.70 EPS. Edwards Lifesciences's revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 26,084 shares of company stock valued at $2,010,382. 1.29% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

EW has been the subject of several recent research reports. Robert W. Baird upped their target price on Edwards Lifesciences from $78.00 to $79.00 and gave the company a "neutral" rating in a report on Friday, July 25th. Argus upgraded Edwards Lifesciences to a "strong-buy" rating in a research note on Thursday, July 10th. Daiwa America raised Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 29th. Stifel Nicolaus boosted their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a "buy" rating in a report on Friday, July 25th. Finally, Evercore ISI upped their price target on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the stock an "in-line" rating in a research report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $85.90.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.